CpG Island Methylator Phenotype May Confer a Survival Benefit From Fluoropyrimidine-Based Adjuvant Chemotherapy on Patients With Stage II or III Colorectal Carcinomas

被引：0
|
作者：
Sung, Young Kyung
Min, Byung-Hoon
Kim, Young-Ho
Chang, Dong Kyung
Kim, Hee Cheol
Park, Cheol Keun
Kim, Kyoung-Mee
机构：
来源：
GASTROENTEROLOGY | 2010年 / 138卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
746
引用
收藏
页码：S102 / S102
页数：1
相关论文
共 50 条
  • [21] MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
    E Cecchin
    G Perrone
    S Nobili
    J Polesel
    E De Mattia
    C Zanusso
    P Petreni
    S Lonardi
    N Pella
    M D'Andrea
    D Errante
    F Rizzolio
    T Mazzei
    I Landini
    E Mini
    G Toffoli
    The Pharmacogenomics Journal, 2015, 15 : 219 - 225
  • [22] Different Prognostic Impacts of Fusobacterium Nucleatum Based on Tumor Location in Stage II/III Colorectal Carcinomas Treated with Adjuvant FOLFOX Chemotherapy
    Kim, Jung Ho
    Cho, Nam-Yun
    Bae, Jeong Mo
    Kang, Gyeong Hoon
    MODERN PATHOLOGY, 2018, 31 : 276 - 276
  • [23] Different Prognostic Impacts of Fusobacterium Nucleatum Based on Tumor Location in Stage II/III Colorectal Carcinomas Treated with Adjuvant FOLFOX Chemotherapy
    Kim, Jung Ho
    Cho, Nam-Yun
    Bae, Jeong Mo
    Kang, Gyeong Hoon
    LABORATORY INVESTIGATION, 2018, 98 : 276 - 276
  • [24] MTHFR-1298 A > C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin
    Cecchin, E.
    Perrone, G.
    Nobili, S.
    Polesel, J.
    De Mattia, E.
    Zanusso, C.
    Petreni, P.
    Lonardi, S.
    Pella, N.
    D'Andrea, M.
    Errante, D.
    Rizzolio, F.
    Mazzei, T.
    Landini, I.
    Mini, E.
    Toffoli, G.
    PHARMACOGENOMICS JOURNAL, 2015, 15 (03): : 219 - 225
  • [25] Effect of age on survival benefit of adjuvant chemotherapy in elderly stage III colon cancer patients: a population-based analysis
    Zuckerman, I. H.
    Davidoff, A. J.
    Onukwugha, E.
    Pandya, N.
    Gardner, J. F.
    Seal, B.
    Obeidat, N.
    Rapp, T.
    Mullins, C. D.
    Choti, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] Transcriptional Subtyping and CD8 Immunohistochemistry Identifies Patients With Stage II and III Colorectal Cancer With Poor Prognosis Who Benefit From Adjuvant Chemotherapy
    Allen, Wendy L.
    Dunne, Philip D.
    McDade, Simon
    Scanlon, Enya
    Loughrey, Maurice
    Coleman, Helen G.
    McCann, Christopher
    McLaughlin, Kristy
    Nemeth, Zsuzsanna
    Syed, Najeeb Ashraf
    Jithesh, Puthen Veettil
    Arthur, Ken
    Wilson, Richard
    Coyle, Vicky M.
    McArt, Darragh
    Murray, Graeme, I
    Samuel, Leslie
    Nuciforo, Paolo
    Jimenez, Jose
    Argiles, Guillem
    Dienstmann, Rodrigo
    Tabernero, Josef
    Picariello, Lucia
    Messerini, Luca
    Nobili, Stefania
    Mini, Enrico
    Sheahan, Kieran
    Ryan, Elizabeth
    Johnston, Patrick G.
    Van Schaeybroeck, Sandra
    Lawler, Mark
    Longley, Daniel B.
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 15
  • [27] KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer
    Deng, Yanhong
    Wang, Li
    Tan, Shuyun
    Kim, George P.
    Dou, Ruoxu
    Chen, Dianke
    Cai, Yue
    Fu, Xinhui
    Wang, Lei
    Zhu, Jun
    Wang, Jianping
    MOLECULAR ONCOLOGY, 2015, 9 (07) : 1341 - 1347
  • [28] CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer
    Xiaofei Zhang
    Hideki Shimodaira
    Hiroshi Soeda
    Keigo Komine
    Hidekazu Takahashi
    Kota Ouchi
    Masahiro Inoue
    Masanobu Takahashi
    Shin Takahashi
    Chikashi Ishioka
    International Journal of Clinical Oncology, 2016, 21 : 1091 - 1101
  • [29] CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer
    Zhang, Xiaofei
    Shimodaira, Hideki
    Soeda, Hiroshi
    Komine, Keigo
    Takahashi, Hidekazu
    Ouchi, Kota
    Inoue, Masahiro
    Takahashi, Masanobu
    Takahashi, Shin
    Ishioka, Chikashi
    International Journal of Clinical Oncology, 2016, 21 (06) : 1091 - 1101
  • [30] Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients
    Yong Huang
    Haijun Yu
    Han Lei
    Conghua Xie
    Yahua Zhong
    Medical Oncology, 2014, 31
12345